title: 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
abstract: 2,2'-Bipyridyl-6-carbothioamide (BPYTA), a synthetic compound with antitumoral activity, is characterized by chelating properties because of the N*-N*-S* tridentate ligand system and is therefore comparable to alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones which are potent inhibitors of ribonucleotide reductase (RR). Electron paramagnetic resonance studies on the small subunit of mouse recombinant RR (R2) demonstrated that BPYTA can destroy the R2 tyrosyl radical only if Fe(II) is present (73% destruction at 50 microM, after 20 min of contact). The R2 inhibition was reversible and time dependent. Studies on tumoral lines confirmed that the main cell target of BPYTA is RR and demonstrated that the iron-complexed form compared to the nonchelated form has some difficulty in crossing the cell membrane. Spectrophotometric and electron paramagnetic resonance studies clearly indicated that BPYTA chelates iron only when this is reduced and that the BPYTA-Fe(II) complex is stable in the presence of oxygen. From reported results we conclude that BPYTA is a powerful RR inhibitor (R2 subunit) which has a different mechanism of action from that of Desferal. It has some properties in common with alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones, but they are not identical. It would be interesting to do further studies on the BPYTA mechanism of action and evaluate the in vivo antitumoral activity of the preformed complex.
authors.affiliation: Institute of Medical Pharmacology, University of Perugia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Nocentini
authors.forename: F
authors.initials: F
authors.lastname: Federici
authors.forename: P
authors.initials: P
authors.lastname: Franchetti
authors.forename: A
authors.initials: A
authors.lastname: Barzi
mesh_terms: D015082:2,2'-Dipyridyl / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002614:Chelating Agents / Q000494:pharmacology; D003676:Deferoxamine / Q000494:pharmacology; D005296:Ferrous Compounds / Q000494:pharmacology*; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000494:pharmacology; D046911:Macromolecular Substances; D051379:Mice; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D013882:Thiosemicarbazones / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000201:enzymology
chemical_list: C078811:2,2'-bipyridyl-6-carbothioamide-ferrous complex; D000970:Antineoplastic Agents; D002614:Chelating Agents; D005296:Ferrous Compounds; D005609:Free Radicals; D046911:Macromolecular Substances; D013882:Thiosemicarbazones; D015082:2,2'-Dipyridyl; C033291:2,2'-bipyridyl-6-carbothioamide; D007501:Iron; D012264:Ribonucleotide Reductases; D003676:Deferoxamine